Nuvectis Files $200M Shelf and $75M ATM, Replacing Prior Programs

summarizeSummary

Nuvectis Pharma filed a new $200M universal shelf and a $75M ATM program with Jefferies, replacing its prior $150M shelf and suspended $60M ATM. This expands potential dilution capacity significantly.

check_boxKey Events · Financing and Capital Events · NVCT

• New $200M Shelf Registration

  Replaces prior $150M shelf; carries forward $34.8M of unsold securities and adds $165.2M of new capacity.

• $75M ATM Program with Jefferies

  New at-the-market program with Jefferies, up from the suspended $60M ATM; commission up to 3.0% of gross proceeds.

• Potential Dilution

  If fully utilized, the $200M shelf represents about 26% of current market cap; the ATM alone could add ~3.2M shares (~10% of outstanding).

• Capital Raising Trend

  Follows $100M offering in June and $115M follow-on in July, indicating continued equity financing needs.

auto_awesomeAnalysis · NVCT · Life Sciences

A new $200 million universal shelf registration has been filed, replacing the prior $150 million shelf. The filing also establishes a $75 million at-the-market (ATM) program with Jefferies, superseding the $60 million ATM that was suspended in June. This significantly expands the company's potential equity issuance capacity. While no shares are sold immediately, the shelf and ATM create a substantial overhang: if fully utilized, the $200 million shelf represents roughly 26% of the current market cap, and the ATM alone could add about 3.2 million shares (about 10% of outstanding). The company has been actively raising capital — a $100 million offering in June and a $115 million follow-on in July — and this filing signals continued reliance on equity financing to fund its pipeline.